Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05586776 · ClinicalTrials.gov registry record · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
A Phase 4 study of Surgical Site Infection, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 2,700
- Enrollment target
- 4
- Study locations
NCT05586776 is a Phase 4 study of Surgical Site Infection that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 2,700 participants, above the 460-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (487% higher). The trial reports 4 study locations across 1 state.
The verdict
NCT05586776, a Phase 4 study of Surgical Site Infection, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,700 participants
- Enrollment target
- 4
- Study locations
Study Summary
The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.
Conditions Studied
Interventions
- DRUG 4% Chlorhexidine Gluconate
- DRUG 2% Mupirocin
- DRUG Soap Without Antiseptic Properties (Placebo)
- DRUG Placebo Nasal Ointment
Study Locations (4)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- University of California, Irvine Medical Center - Orange
- University of California, Davis Medical Center - Sacramento
- University of California, San Francisco Medical Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,700 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05586776
The ClinicalTrials.gov registry entry for NCT05586776 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 2,700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 460-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (487% higher). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Surgical Site Infection appearing as the primary indexed condition, and to 4 interventions - of which 4% Chlorhexidine Gluconate is the first listed.
NCT05586776 reports 4 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05586776 about?
NCT05586776 is a clinical study titled "Decolonization to Reduce After-Surgery Events of Surgical Site Infection". The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel...
What is the current status of trial NCT05586776?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 2,700 participants. The study started on 2023-01-17. Estimated completion is 2028-12.
What conditions does trial NCT05586776 study?
This clinical trial studies the following conditions: Surgical Site Infection.
What interventions are being tested in trial NCT05586776?
The interventions under investigation include: 4% Chlorhexidine Gluconate (DRUG), 2% Mupirocin (DRUG), Soap Without Antiseptic Properties (Placebo) (DRUG), Placebo Nasal Ointment (DRUG).
Who is sponsoring clinical trial NCT05586776?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05586776 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Site Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ostomy Primary Closure With 0.1% Betaine/Polyhexanide Wound Irrigation Compared to Pursestring Closure
RECRUITING · Phase 4
-
Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery
RECRUITING · Phase 4
-
PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)
ACTIVE NOT RECRUITING · Phase 4
-
Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures
COMPLETED · Phase 4
-
Topical Antibiotic Prophylaxis for Eyelids
COMPLETED · Phase 4
-
Multicenter Infection Surveillance Study Following Open Heart Surgery
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.